1990;163:37 40. 3. Nakhjavan FK, Katz MR, Maranhao V, et al. Analysis of influence of cat- echolamine and tachycardia during supine exercise in patients with mitral stenosis and sinus rhythm. Br Heart J. 1969;31:753 61. 4. Bhatia ML, Shrivastava S, Roy SB. Immediate haemodynamic effects of a beta adrenergic blocking agent-propranolol-in mitral stenosis at fixed heart rates. Br Heart J. 1972;34:638 44. 5. Lydakis C, Lip GY, Beevers M, et al. Atenolol and fetal growth in pregnan- cies complicated by hypertension. Am J Hypertens. 1999;12:541 7. 6. Ruys TP, Maggioni A, Johnson MR, et al. Cardiac medication during preg- nancy, data from the ROPAC. Int J Cardiol. 2014;177:124 8. 7. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC guidelines for the management of cardiovascular diseases during preg- nancy. Eur Heart J. 2018;39:3165 241. 8. Taylor J. The first ESC guidelines on the management of cardiovascular diseases during pregnancy. Eur Heart J. 2011;32:3055 6. 9. Schaefer C. Angiotensin II-receptor-antagonists: further evidence of feto- toxicity but not teratogenicity. Birth Defects Res Part A Clin Mol Teratol. 2003;67:591 4. 10. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital mal- formations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354:2443 51. 11. Shotan A, Widerhorn J, Hurst A, et al. Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evi- dence, potential mechanisms, and recommendations for use. Am J Med. 1994;96:451 6. 12. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130:2071 104. 13. January CT, Wann LS, Calkins H, et al. 